JP2008534692A - テモゾロミドの単位投薬形態 - Google Patents

テモゾロミドの単位投薬形態 Download PDF

Info

Publication number
JP2008534692A
JP2008534692A JP2008523051A JP2008523051A JP2008534692A JP 2008534692 A JP2008534692 A JP 2008534692A JP 2008523051 A JP2008523051 A JP 2008523051A JP 2008523051 A JP2008523051 A JP 2008523051A JP 2008534692 A JP2008534692 A JP 2008534692A
Authority
JP
Japan
Prior art keywords
days
patient
per day
day
day cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008523051A
Other languages
English (en)
Japanese (ja)
Inventor
ジャクリーン ローズ バーシュ，
マーク マンゾー，
スマント ラマチャンドラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of JP2008534692A publication Critical patent/JP2008534692A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2008523051A 2006-06-26 2007-06-25 テモゾロミドの単位投薬形態 Withdrawn JP2008534692A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81662306P 2006-06-26 2006-06-26
PCT/US2007/014761 WO2008002544A2 (en) 2006-06-26 2007-06-25 Unit dosage forms of temozolomide

Publications (1)

Publication Number Publication Date
JP2008534692A true JP2008534692A (ja) 2008-08-28

Family

ID=38704663

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008523051A Withdrawn JP2008534692A (ja) 2006-06-26 2007-06-25 テモゾロミドの単位投薬形態

Country Status (13)

Country Link
EP (1) EP1901740A2 (es)
JP (1) JP2008534692A (es)
KR (2) KR20100055543A (es)
CN (1) CN101309686A (es)
AR (1) AR061618A1 (es)
AU (1) AU2007221979A1 (es)
BR (1) BRPI0702847A (es)
CA (1) CA2610439A1 (es)
CL (1) CL2007001864A1 (es)
NO (1) NO20074913L (es)
TW (1) TWI326598B (es)
WO (1) WO2008002544A2 (es)
ZA (1) ZA200708280B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526038B (zh) * 2011-01-12 2013-09-11 北京人福军威医药技术开发有限公司 替莫唑胺的脑靶向药物组合物及其应用
WO2017165266A1 (en) * 2016-03-21 2017-09-28 Duke University Sequential anti-cancer treatment
US11147810B2 (en) 2017-03-13 2021-10-19 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023185A1 (es) * 1999-03-30 2002-09-04 Schering Corp Tratamiento de cancer mejorado con temozolomida
AU2005304672B2 (en) * 2004-11-09 2010-03-11 Schering Corporation Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level

Also Published As

Publication number Publication date
TW200808803A (en) 2008-02-16
CN101309686A (zh) 2008-11-19
WO2008002544A3 (en) 2008-02-07
AU2007221979A1 (en) 2008-01-10
WO2008002544A2 (en) 2008-01-03
CL2007001864A1 (es) 2008-02-08
NO20074913L (no) 2009-03-26
TWI326598B (en) 2010-07-01
BRPI0702847A (pt) 2008-04-01
KR20080015777A (ko) 2008-02-20
EP1901740A2 (en) 2008-03-26
ZA200708280B (en) 2009-03-25
CA2610439A1 (en) 2007-12-26
KR20100055543A (ko) 2010-05-26
AR061618A1 (es) 2008-09-10
AU2007221979A9 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
AU2005304672B2 (en) Improved dosing regimen of temozolomide for treating cancer based on the patient's MGMT level
Plummer et al. Phase I study of the poly (ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
Michels et al. Predictive biomarkers for cancer therapy with PARP inhibitors
US10221459B2 (en) Compositions and methods of treating cancer harboring PIKC3A mutations
CN104968323B (zh) Crl4泛素连接酶抑制剂及其用途
US20100210700A1 (en) Methods of treatment using intravenous formulations comprising temozolomide
Xiao et al. Chemoresistance to depsipeptide FK228 [(E)-(1S, 4S, 10S, 21R)-7-[(Z)-ethylidene]-4, 21-diisopropyl-2-oxa-12, 13-dithia-5, 8, 20, 23-tetraazabicyclo [8, 7, 6]-tricos-16-ene-3, 6, 9, 22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines
US20080090242A1 (en) Panel of biomarkers for prediction of fti efficacy
JP2008534692A (ja) テモゾロミドの単位投薬形態
US20080319039A1 (en) Unit dosage forms of temozolomide
Stachelek et al. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase β is accentuated by BRCA2 mutation
US20100240723A1 (en) Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
MX2007012093A (es) Formas de dosificacion unitaria de temozolomida
CA2472846A1 (en) Methods for assessing and treating leukemia
US20220211710A1 (en) Compositions and methods for treating cancer with nucleoside-metabolism modulators
WO2021074338A1 (en) Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy
Di Nicolantonio Multidrug resistance in solid tumours
Davies et al. Role of Topoisomerase II α and β Isozymes in Determining Drug Resistance in vitro and in vivo

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101221